

What is claimed is:

CLAIMS

1. A zinc salt of 2-[3-[(3*R*)-3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-(2,2-diphenylethyl)amino]butoxy]phenyl]acetic acid (Compound 1).
2. The zinc salt of claim 1, wherein the zinc salt is a 2:1 (Compound 1:zinc) salt.
3. The zinc salt of claim 1 or 2, wherein the zinc salt is amorphous.
4. The zinc salt of any one of claims 1 to 3 having less than 1% mass loss up to decomposition as measured by thermal gravimetric analysis.
5. An aluminum salt of Compound 1.
6. The aluminum salt of claim 5, wherein the aluminum salt is a 3:1 (Compound 1:aluminum) salt.
7. The aluminum salt of claim 5 or 6, wherein the aluminum salt is amorphous.
8. The aluminum salt of any one of claims 5 to 7 having less than 1% mass loss up to decomposition as measured by thermogravimetric analysis.
9. A pharmaceutical composition comprising the zinc or aluminum salt of any one of claims 1 to 8 and a pharmaceutically acceptable excipient.
10. The pharmaceutical composition of claim 9, wherein the pharmaceutical composition comprises less than 1.5 weight % of sodium.
11. The pharmaceutical composition of claim 10, wherein the pharmaceutical composition is substantially free of the 1:1 sodium salt of Compound 1.
12. The pharmaceutical composition of any one of claims 9 to 11, wherein the pharmaceutical composition is in unit dosage form.
13. A method of treating cancer, the method comprising administering an effective amount of the zinc or aluminum salt of any one of claims 1 to 8 or the pharmaceutical composition of any one of claims 9 to 12.
14. The method of claim 13, wherein the cancer is breast cancer, colon cancer, renal cell cancer, lung cancer, hepatocellular carcinoma, gastric cancer, ovarian cancer, pancreatic cancer, esophageal cancer, prostate cancer, sarcoma, bladder cancer, head and neck cancer, glioblastoma, diffuse large B-cell lymphoma, leukemia, or melanoma.

15. The method of claim 14, wherein the cancer is metastatic cancer.
16. The method of claim 15, wherein the effective amount comprises an amount effective to suppress metastatic colonization of said cancer.
17. A method of producing a zinc salt of Compound 1, the method comprising combining Compound 1, or a salt thereof, and a zinc salt under conditions sufficient to produce the zinc salt of Compound 1.
18. The method of claim 17, wherein the zinc salt of Compound 1 is a 2:1 (Compound 1:zinc) salt.
19. The method of claim 17 or 18, wherein the Compound 1, or salt thereof, is a 1:1 (Compound 1:sodium) salt.
20. The method of any one of claims 17 to 19, wherein the zinc salt is zinc chloride.
21. The method of any one of claims 17 to 19, wherein the zinc salt is zinc acetate.
22. The method of claim any one of claims 17 to 21, wherein the method comprises dissolving the Compound 1, or salt thereof, and the zinc salt in a solvent to form a mixture.
23. The method of claim 22, wherein the method further comprises cycling the temperature of the mixture between ambient temperature and 40 °C.
24. The method of claim 23, wherein the cycling is performed in 4-hour cycles.
25. The method of claim 24, wherein the cycling is performed for 24 hours.
26. The zinc salt of claim 3, wherein the zinc salt has a peak with increased intensity relative to the free acid at about $1590 \pm 10 \text{ cm}^{-1}$ and a peak with reduced intensity relative to the free acid at about $1710 \pm 10 \text{ cm}^{-1}$ as measured by Fourier-transform infrared spectroscopy (FTIR).